ArticleThe American journal on addictions
Clinician beliefs and attitudes about buprenorphine/naloxone diversion.
Article in The American journal on addictions. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 1 synthesis or guideline pooled it, 35 citations in OpenAlex.
- A systematic review of patients' and providers' perspectives of medications for treatment of opioid use disorder.Journal of substance abuse treatment · 2020Pooled it
- Video directly observed therapy for patients receiving office-based buprenorphine - A pilot randomized controlled trial.Drug and alcohol dependence · 2021Trial
- Efficacy of Tramadol Extended-Release for Opioid Withdrawal: A Randomized Clinical Trial.JAMA psychiatry · 2017Trial
- Article
- Association between Prescribers' Perceptions of the Utilization of Medication for Opioid Use Disorder and Opioid Dependence Treatability.Healthcare (Basel, Switzerland) · 2022Article
- Assessing the feasibility, usability and acceptability of theDrug and alcohol dependence reports · 2022Article
- Alternative use of buprenorphine among people who use opioids in three U.S. Cities.Substance abuse · 2022Article
- The relationship between patients' income and education and their access to pharmacological chronic pain management: A scoping review.Canadian journal of pain = Revue canadienne de la douleur · 2022Article
- "You are not clean until you're not on anything": Perceptions of medication-assisted treatment in rural Appalachia.The International journal on drug policy · 2020Article
- Organizational Facilitators and Barriers to Medication for Opioid Use Disorder Capacity Expansion and Use.The journal of behavioral health services & research · 2020Article
- Video directly observed therapy intervention using a mobile health application among opioid use disorder patients receiving office-based buprenorphine treatment: protocol for a pilot randomized controlled trial.Addiction science & clinical practice · 2020Article
- Therapy without a prescription: buprenorphine/naloxone diversion and the therapeutic assemblage in Taiwan.Sociology of health & illness · 2020Article
- Prevalence and treatment of opioid use disorders among primary care patients in six health systems.Drug and alcohol dependence · 2020Observational
- Building a Group-Based Opioid Treatment (GBOT) blueprint: a qualitative study delineating GBOT implementation.Addiction science & clinical practice · 2019Article
- Barriers and facilitators to buprenorphine use for opioid agonist treatment: protocol for a scoping review.BMJ open · 2019Article
- Perceptions and practices addressing diversion among US buprenorphine prescribers.Drug and alcohol dependence · 2018Article
- Interprofessional prescription opioid abuse communication among prescribers and pharmacists: A qualitative analysis.Substance abuse · 2018Article
- Practice Guidance for Buprenorphine for the Treatment of Opioid Use Disorders: Results of an Expert Panel Process.Substance abuse · 2015Article
- Illicit buprenorphine use, interest in and access to buprenorphine treatment among syringe exchange participants.Journal of substance abuse treatment · 2015Article
- Evidence on Buprenorphine Dose Limits: A Review.Journal of addiction medicineReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 5 institutions in 1 country.
Funding
Abstract
BACKGROUND AND
objectivesConcern about diversion of buprenorphine/naloxone (B/N) in the United States may affect prescribing patterns and policy decisions. This study examines addiction treatment clinician beliefs and attitudes regarding B/N diversion.
methodsParticipants (n = 369) completed a 34-item survey in 2010 during two national symposia on opioid dependence. We conducted multivariable regression, examining the relationship of perceived danger from B/N diversion with clinician characteristics and their beliefs about B/N treatment and diversion. We compared causal beliefs about diversion among clinicians with and without B/N treatment experience.
resultsForty percent of clinicians believed that B/N diversion is a dangerous problem. The belief that B/N diversion increases accidental overdoses in the community was strongly associated with perceived danger from B/N diversion. CONCLUSIONS AND SCIENTIFIC SIGNIFICANCE: Attitudes and beliefs, not education level, were associated with clinician's perceived danger from B/N diversion. Clinicians with greater B/N patient experience were more likely to believe treatment access barriers are the major cause of B/N diversion.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.